Dr Richard A Anderson, Professor of Clinical Reproductive Science at the University of Edinburgh, was commissioned by ACART to produce a technical report on:
- information about the cryopreservation of ovarian tissue in New Zealand and its subsequent use and,
- the feasibility of the use of cryopreserved ovarian tissue in New Zealand in the near future.
- Female fertility preservation is an area of significant clinical activity in many countries, with the main driver being dramatic improvements in cancer survival rates.
- Clinical practice characterises the field, with the lack of basic human research
- In 2004, the first baby was born from the use of cryopreserved ovarian tissue. There are published reports on fewer than a dozen babies born from the technique.
- There is extremely limited information on the safety and efficacy of the procedure in humans, and no information about long term outcomes for children.
- No cases have been reported of malignant disease following reimplantation of cryopreserved ovarian tissue.